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Abstract
Background Degludec is a long-acting insulin with a longer duration of action and a greater day-to-day reproducibility of 
absorption in comparison with previous long-acting insulin formulations. The aim is the definition of the change in insulin 
needs in patients switching from detemir/glargine to degludec in real-life conditions.
Methods In this retrospective cohort observational study, all outpatients with either type 1 or type 2 diabetes, starting therapy 
with degludec insulin—after a prior treatment with either detemir or glargine insulin for at least 6 months—were included.
Results The analysis was performed on 266 patients, 172 and 96 with type 1 and type 2 diabetes, respectively. The equa-
tions describing the relationship between baseline and follow-up doses of basal insulin (6 months) were Y = 3.39 + 0.78X 
and Y = 0.44 + 0.69X, in patients receiving detemir/glargine either once or twice daily, respectively (Y = degludec dose at 
6 months and X = basal insulin dose at switch). The corresponding equations for prandial insulin doses were y = 1.83 + 0.83*x 
and y = 2.85 + 0.80*x for those on pre-switch once or twice-daily basal insulin, respectively. In type 2 diabetes, the switch 
was associated with a reduction of basal insulin doses only in those with a prior twice-daily treatment with basal insulin. The 
reduction of prandial insulin reached statistical significance only in patients previously treated with basal insulin once daily.
Conclusions The present results provide a suggestion for a simple method for the adjustment of basal and prandial insulin 
doses in type 1 diabetic patients, switching from glargine or detemir to degludec.
Keywords Type 1 diabetes · Type 2 diabetes · Insulin · Degludec · Basal insulin · Prandial insulin
Introduction
Degludec is a long-acting insulin used in the treatment of 
diabetes. In comparison with previously available long-
acting insulin formulations (human NPH insulin, glargine, 
and detemir), degludec has a longer duration of action and a 
greater day-to-day reproducibility of absorption after subcu-
taneous injection [1–3]. As a consequence, the use of deglu-
dec insulin is associated with a lower risk of overall and 
nocturnal hypoglycemia, both in type 1 and type 2 diabetes 
[4–6]. These advantages may prompt physicians to switch 
from glargine or detemir to degludec in some patients, to 
reduce hypoglycemic risk.
In randomized clinical trials, when compared to either 
glargine (in the 100 U/ml formulation) or detemir, after an 
appropriate titration, the use of degludec is associated with 
a significant reduction of insulin doses, both for long-acting 
(basal) and short-acting (prandial) insulin [5–7]. As a con-
sequence, it could be necessary to reduce basal and pran-
dial insulin doses when switching from glargine or detemir 
to degludec. In patients with type 1 diabetes, the use of 
degludec, in comparison with glargine, is associated with 
a 12–13% reduction of both basal and prandial daily insu-
lin doses [6]. The reduction in basal insulin doses has been 
reported to be greater in patients who were previously on 
two injections of basal (detemir or glargine) insulin, in com-
parison with those who were previously treated with long-
acting insulin once daily [8–11]. A similar difference was 
observed in trials on type 2 diabetes on basal-only insulin 
regimens, whereas no significant reduction of insulin doses 
has been associated with degludec in patients with type 2 
diabetes on basal-bolus therapy [6].
Although suggestive, data obtained in randomized clini-
cal trials cannot be automatically transferred to routine 
clinical practice. In particular, the relatively aggressive dose 
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titration algorithms for basal insulin used in clinical trials, 
with frequent patient contacts and accurate supervision, 
are not easily applied in real-world conditions; in addition, 
patients enrolled in clinical trials are not totally representa-
tive of the population of patients receiving basal insulin in 
clinical practice. For those reasons, observational data can 
add further information on modifications of insulin doses 
in the switch from glargine or detemir to degludec. A meta-
analysis of observational studies on Japanese patients with 
type 1 or 2 diabetes switching from glargine or detemir to 
degludec reported a reduction of 9 and 5.5% of basal insulin 
doses in patients with type 1 and type 2 diabetes, respec-
tively [12]. In a small 3-month prospective observational 
study performed in European patients with type 1 diabetes, 
the switch from twice-daily glargine or detemir to once daily 
degludec was associated with a 24% reduction of basal insu-
lin dose, together with a 10% reduction of prandial insulin 
dose [13].
In the present study, we retrospectively assessed the vari-
ation of insulin doses 6 months after the switch from glar-
gine or detemir to degludec. The aim is the definition of the 
change in insulin needs in different subgroups of patients 
(type 1 and type 2 diabetes; prior therapy with once- or 
twice-daily basal insulin; prior therapy with detemir or glar-
gine) in real-life conditions, to gather information useful for 
the adjustment of insulin doses at the moment of the switch.
Subjects, materials, and methods
The study was designed as a retrospective, single-center, 
cohort observational study. All outpatients with either type 1 
or type 2 diabetes, who started therapy with degludec insulin 
between October 1st, 2014, and November 1st, 2016, after a 
prior treatment with either detemir or glargine insulin for at 
least 6 months, were included in the study, provided that they 
gave their written informed consent. Patients with HbA1c 
greater than 80 mmol/mol or ketoacidosis at the moment of 
the switch from detemir/glargine to degludec were excluded, 
as well as those with critical illness and those needing corti-
costeroid therapy. The analysis was performed on all patients 
for whom a follow-up determination of HbA1c and informa-
tion on insulin doses were available from clinical records 6 
(± 2) months after the switch.
According to the local standards, basal insulin is adminis-
tered at bedtime if once daily, whereas the second injection 
of basal insulin, when needed, is added before lunch. For 
degludec, the standard is once daily at bedtime. It is pos-
sible that a different timing was used in some patients, but 
this information is not available from clinical report forms.
Information on demographic and clinical characteristics 
at the beginning of degludec therapy, together with data on 
HbA1c and insulin doses at switch and at follow-up, was 
collected from clinical records. Episodes of severe hypo-
glycemia (i.e., requiring third-party assistance) during 
the 6 months preceding the switch, and in the following, 
6 months were also collected from clinical records.
Data are reported as mean ± SD, or as median [quartiles], 
depending on their distribution. Comparisons at different 
timepoints were performed using Levene’s or Wilcoxon’s 
test. Correlation analyses were performed applying Spear-
man’s method. Multivariate analyses were performed using 
stepwise linear regression models. All analyses were per-
formed on SPSS 24.
The study was approved by the local ethical board.
Results
Characteristics of the sample
The analysis was performed on a sample of 266 patients, 
172 and 94 with type 1 and type 2 diabetes, respectively. The 
main demographic and clinical characteristics of patients 
at the moment of the switch from either detemir or glar-
gine to degludec insulin is summarized in Table 1. Among 
patients with type 1 diabetes, 91 (53%) and 81 (47%) had a 
prior treatment with detemir or glargine, respectively—all 
in combination with prandial therapy with a rapid-acting 
analogue (lispro, aspart, or glulisine). Among patients with 
type 2 diabetes, 59 (63%) and 35 (37%) had been previously 
treated with detemir or glargine, respectively. Basal insulin 
was associated with prandial insulin in 85 (80%) patients; in 
addition, 54 (57.4%) patients were treated with metformin, 5 
with DPP4i, 6 with SU, 2 with acarbose, 1 with pioglitazone 
and 1 with liraglutide.
Among patients with type 1 diabetes, the majority of 
those treated with detemir received two daily injections 
of basal insulin (59 and 32 with two and one injection), 
whereas the majority of those on glargine insulin received 
basal insulin once daily (15 and 66 with two and one injec-
tions). Among patients with type 2 diabetes, only 29 and 
4 on detemir and glargine, respectively, were treated with 
basal insulin twice daily. Six months after the switch to 
degludec, all patients were treated with basal insulin once 
daily. After 6 months from the switch, Body Mass Index 
was not significantly different from baseline (25.1 ± 3.8 and 
32.6 ± 7.4 kg/m2 in patients with type 1 and type 2 diabetes, 
respectively).
Type 1 diabetes
After 6 months from the switch, HbA1c showed a significant 
reduction from baseline (58.6 ± 9.6 versus 62.0 ± 9.4 mmol/
mol; p < 0.001). In addition, a significant reduction of both 
basal and prandial insulin doses was observed (18 [13; 23] 
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Table 1  Main demographic and clinical characteristics of included patients
Type 2 diabetes p Type 1 diabetes p
All (n = 94) 1 Injection 
(n = 61)
2 Injections 
(n = 33)
All (n = 172) 1 injection 
(n = 98)
2 injections 
(n = 74)
Age (years) 46.3 ± 14.9 47.9 ± 16.7 44.1 ± 11.8 0.51 70.3 ± 8.7 70.5 ± 8.8 70 ± 8.6 0.63
Women (n, %) 88 (51.2) 50 (51.0) 34 (45.9) 0.51 47 (50.0) 28 (59.6) 19 (40.4) 0.28
Body Mass Index 
(Kg/m2)
25 ± 3.8 25.0 ± 3.6 25.1 ± 4.0 0.86 32.4 ± 7.6 32.3 ± 7.3 32.6 ± 8.3 0.65
Duration of diabe-
tes (years)
20.8 ± 12.3 19 ± 12.5 23.1 ± 11.8 0.73 21.2 ± 10.4 21.6 ± 11.2 20.5 ± 9.1 0.22
HbA1c (%) 62.0 ± 9.4 61.3 ± 8.9 62.9 ± 10.1 0.14 65.3 ± 10.1 66.2 ± 10.5 63.6 ± 8.7 0.19
Creatinine (mg/dl) 0.77 ± 0.18 0.78 ± 0.17 0.76 ± 0.18 0.90 1.12 ± 0.52 1.17 ± 0.51 1.06 ± 0.53 0.24
Total cholesterol 
(mg/dl)
178.8 ± 31.7 180.5 ± 32.0 176.6 ± 31.2 0.82 171.4 ± 33.7 168.3 ± 33.0 176.3 ± 34.7 0.98
HDL-cholesterol 
(mg/dl)
60.9 ± 15.4 61.7 ± 16.2 59.9 ± 14.4 0.65 49.1 ± 12.9 49.6 ± 12.5 48.4 ± 13.7 0.74
Triglycerides (mg/
dl)
86.6 ± 43.8 82.6 ± 34.9 91.9 ± 53.0 0.018 143.7 ± 65.5 143.8 ± 70.0 143.5 ± 57.9 0.97
LDL-cholesterol 
(mg/dl)
100.7 ± 26.1 102.3 ± 25.9 98.6 ± 26.4 0.53 94.4 ± 28.0 91.7 ± 26.5 99.2 ± 30.3 0.31
Pharmacological treatments
 Insulin detemir 
(n. %)
91 (52.9) 32 (32.7) 59 (79.0) < 0.001 59 (62.8) 30 (49.2) 29 (87.9) < 0.001
 Insulin glargine 
(n. %)
81 (47.1) 66 (67.3) 15 (20.3)  < 0.001 35 (37.2) 31 (50.8) 4 (12.1) < 0.001
 Prandial insulin 
dose (IU/die)
26.3 ± 12.8 27.1 ± 13.5 25.3 ± 12.0 0.97 37.2 ± 25.2 37.5 ± 24.0 36.8 ± 27.7 0.70
 Basal insulin dose 
(IU/die)
22.4 ± 10.5 18.2 ± 9.1 27.9 ± 9.8 0.95 33.2 ± 21.4 24.7 ± 13.3 48.9 ± 24.7 < 0.001
 Metformin (n, %) 32 (18.6) 17 (52.8) 15 (47.3) 0.89 54 (57.4) 43 (80.2) 11 (20.0) < 0.001
 Acarbose(n. %) – – – 2 (2.1) 2 (3.3) 0 (0.0) 0.29
 Sulfonylureas 
(n. %)
6 (6.4) 3 (4.9) 3 (9.1) 0.43
 Dypeptidyl Pepti-
dase-4 inhibi-
tors (n. %)
– – – – 5 (5.3) 4 (6.6) 1 (3.0) 0.47
 Glucagon-like 
peptide-1 ana-
logues (n. %)
– – – – 1 (1.1) 1 (1.6) 0 (0.0) 0.46
Medical history (n. %)
 Active smokers 33 (19.2) 18 (10.5) 15 (8.7) 0.85 4 (4.3) 2 (3.3) 2 (6.1) 0.24
 Ex-smokers 31 (18) 19 (11) 12 (7.0) 0.85 30 (31.9) 23 (37.7) 7 (21.2) 0.73
 Hypertension 51 (29.7) 32 (18.6) 19 (11) 0.32 84 (89.4) 55 (90.2) 29 (89.4) 0.88
 Ischemic heart 
disease
8 (4.7) 5 (2.9) 3 (1.7) 0.75 35 (37.2) 25 (41.0) 10 (30.3) 0.43
 Stroke 3 (1.7) 1 (0.6) 2 (1.2) 0.40 12 (12.8) 9 (14.8) 3 (9.1) 0.37
 Renal impairment 
(eGFR < 90 ml/
min)
25 (14.5) 18 (10.5) 7 (4.1) 0.10 71 (75.5) 46 (75.4) 25 (75.8) 0.75
 Microalbuminuria 21 (12.3) 12 (7.0) 9 (5.3) 0.97 42 (44.7) 30 (50) 12 (36.4) 0.21
 Diabetic retin-
opathy
37 (21.5) 19 (11.0) 18 (10.5) 0.43 45 (47.9) 29 (47.5) 16 (48.5) 0.56
 Diabetic neuropa-
thy
27 (15.7) 17 (10.0) 10 (5.8) 0.49 38 (40.4) 29 (47.5) 9 (27.3) 0.060
 Foot ulcers 4 (2.3) 2 (1.2) 2 (1.2) 0.78 6 (6.4) 6 (9.8) 0 (0.0) 0.33
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versus 22 [14; 29] UI/die; 22 [16; 30] versus 23 [17; 32] UI/
die; both p < 0.001). The initial dose of degludec prescribed 
was 20 [13; 29] UI/die. The switch to degludec was associ-
ated with a reduction of basal insulin doses only in patients 
with a prior twice-daily treatment, but not in those previ-
ously receiving basal insulin once daily; furthermore, the 
reduction of basal insulin doses was significant in patients 
previously treated with detemir, but not with glargine. A 
significant reduction of prandial insulin was observed in 
patients previously treated with basal insulin once or twice 
daily, irrespective of the type of prior insulin (Tables 2, 3). 
Episodes of severe hypoglycemia (one per patient) were 
recorded in 3 and 2 subjects before and after the switch, 
respectively.
In type 1 diabetes, percent reduction of basal insulin 
doses showed a significant direct correlation with baseline 
basal doses (r = 0.51, p < 0.001) and duration of diabetes 
(r = 0.30, p < 0.001), whereas percent reduction of prandial 
insulin showed a significant direct correlation with base-
line prandial doses (r = 0.21, p = 0.005) and age (r = 0.24, 
Table 1  (continued)
Type 2 diabetes p Type 1 diabetes p
All (n = 94) 1 Injection 
(n = 61)
2 Injections 
(n = 33)
All (n = 172) 1 injection 
(n = 98)
2 injections 
(n = 74)
Previous hypoglycemic episodes (n. %)
 Severe hypogly-
cemia
6 (3.5) 5 (3.0) 1 (0.6) 0.18 3 (3.2) 1 (1.6) 2 (6.1) 0.24
 Nocturnal hypo-
glycemia
153 (89) 83 (48) 70 (41) 0.04 60 (63.8) 32 (52.5) 28 (84.8) 0.002
Table 2  Variation in insulin daily doses in subgroups with 1 or 2 basal insulin injection/die at the switch
DM diabetes mellitus, Inj. injection
Group Prandial doses Basal doses
At the switch At 6 months Difference  %  
[95%, CI]
p At the switch At 6 months Difference  %  
[95%, CI]
p
DM 1
 All 23 [17; 32] 22 [16; 30] − 7 [− 19; 0] < 0.001 22 [14; 29] 18 [13, 23] − 13 [− 27, 0] < 0.001
 1 Inj 25 [18; 34] 23 [16; 30] − 0 [− 12; 7] < 0.001 16 [11, 25] 16 [12, 22] − 8 [− 20; 0]  0.110
 2 Inj 22 [16; 30] 20 [16, 28] − 5 [− 17; 4] 0.006 28 [22; 33] 19 [14, 23] − 28 [− 38; − 20] < 0.001
DM 2
 All 33 [21; 51] 30 [20; 45] − 5 [− 17; 1] 0.006 28 [18; 45] 24 [16; 42] − 7 [− 23,11] 0.006
 1 Inj 37 [20; 52] 31 [21; 45] − 5 [− 18; 4] 0.055 21 [14; 34] 21 [15; 34] 0 [− 12; 17] 0.550
 2 Inj 30 [20; 51] 26 [17; 46] − 6 [− 16; 0] 0.042 45 [26; 68] 35 [18; 57] − 20 [− 36; − 8] < 0.001
Table 3  Variation in insulin daily doses in subgroups pre-treated with detemir or glargine at the switch
DM diabetes mellitus, Inj. injection
Group Prandial doses Basal doses
At the switch At 6 months Difference % p At the switch At 6 months Difference % p
DM 1
 All 23 [17; 32] 22 [16; 30] − 7 [− 19, 0] < 0.001 22 [14; 29] 18 [13, 23] − 13 [− 27, 0] < 0.001
 Detemir 22 [17; 34] 20 [16; 30] − 7 [− 22; − 0] < 0.001 23 [14; 32] 16 [13, 22] − 22 [− 34; − 7] < 0.001
 Glargine 24 [18; 32] 23 [16; 30] − 5 [− 15; 0] 0.003 22 [13, 27] 19 [13, 24] − 7 [− 16; 1] < 0.001
DM 2
 All 33 [21; 51] 30[ 20; 45] − 5 [− 17,1] 0.006 28 [18; 45] 24 [16; 42] − 7 [− 23; 11] 0.006
 Detemir 37 [22; 60] 29 [17; 44] − 6 [− 18; 0] < 0.001 34 [18; 50] 24 [16; 40] − 11 [− 29; 0] < 0.001
 Glargine 31 [18; 40] 30 [22; 49] − 5 [− 14; 9] 0.96 22 [14; 38] 24 [16; 43] + 4 [− 10, 25] 0.003
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p = 0.002), and an inverse correlation with eGFR (r = − 0.15, 
p = 0.049). No significant correlation was detected with 
baseline HbA1c (data not shown). A linear regression model 
was used for multivariate analysis, with percent variation of 
basal insulin dose as dependent variable, including dura-
tion of diabetes, basal insulin dose, number of basal insu-
lin daily injections at enrolment, and type of basal insulin 
(detemir or glargine) as putative determinants. The variation 
of basal insulin doses was significantly correlated with dura-
tion of diabetes (β = − 0.126; p = 0.50), number of injec-
tions (β = − 0.369; p < 0.001), and doses of basal insulin 
before switch (β = − 0.344 p < 0.001), but not prior type of 
basal insulin. A similar model was used for the variation of 
prandial insulin doses, adjusting for duration of diabetes, 
baseline prandial insulin doses, number of basal insulin daily 
injections at enrolment, type of basal insulin (detemir or 
glargine), age, and eGFR. The percent variation of prandial 
insulin doses showed a significant correlation only with the 
number of daily basal insulin injections before the switch 
(β = − 0.57; p < 0.001).
In a linear regression model, when analyzing separately 
patients with type 1 diabetes receiving detemir/glargine 
either once or twice daily, the equations describing the 
relationship between baseline and follow-up doses of basal 
insulin were Y = 3.39 + 0.78X and Y = 0.44 + 0.69X, respec-
tively, where Y = degludec dose at 6 months and X = basal 
insulin dose at switch (Fig. 1a). The corresponding equa-
tions for prandial insulin doses were y = 1.83 + 0.83*x and 
y = 2.85 + 0.80*x for those on pre-switch once or twice-daily 
basal insulin, respectively (Fig. 1b).
Type 2 diabetes
In patients with type 2 diabetes, 6-month HbA1c was signifi-
cantly lower than baseline (58.7 ± 9.7 versus 65.3 ± 10.1, 
p < 0.001). Both basal and prandial insulin doses showed a 
significant reduction during the 6-month follow-up (24 [16; 
42] versus 28 [18; 45] UI/die difference, 30 [20; 45] versus 
33 [21; 51] UI/die, respectively, both p = 0.006). The initial 
dose of degludec prescribed was 28 [16; 46] UI/die. The 
switch to degludec was associated with a reduction of basal 
insulin doses only in those with a prior twice-daily treatment 
with basal insulin. The reduction of prandial insulin reached 
statistical significance only in patients previously treated 
with basal insulin once daily (Tables 2, 3). One patient has 
experienced one episode of severe hypoglycemia in the 
6 months before the switch, and another one reported one 
episode during the 6-month follow-up after the switch. Dur-
ing the 6-month follow-up after the switch, treatment with 
sulfonylurea (gliclazide ER 30 mg) was withdrawn in one 
patient; no other variations in non-insulin therapy resulted 
from clinical records.
At univariate analysis, in patients with type 2 diabetes, the 
percent reduction of basal insulin doses showed a significant 
direct correlation with baseline doses (r = 0.36 p < 0.001), 
whereas prandial insulin showed a significant direct corre-
lation with diabetes duration (r = 0.27 p = 0.01). No signifi-
cant correlation was detected with baseline HbA1c (data not 
shown). At multivariate analysis, using the same models speci-
fied above, the percent variation of basal insulin doses main-
tained a significant correlation with prior doses of basal insulin 
and with diabetes duration (β = − 0.28 [p = 0.026] and − 0.21 
[p = 0.044], respectively). The variation of prandial insulin 
doses was significantly correlated with the number of daily 
basal insulin injections and with diabetes duration (β = − 0.29 
[p = 0.006] and − 0.21 [p = 0.039], respectively).
A
 B
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m
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Prandial analogue at baseline (IU/die)
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1 injecon/die
2 injecons/die
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both p<0.001
y= 0.80*x + 2.85
Fig. 1  a Describes the relationship between baseline and follow-up 
doses of basal insulin in type 1 diabetic patients receiving detemir/
glargine either once or twice daily; b describes the relationship 
between baseline and follow-up doses of prandial insulin in type 1 
diabetic patients receiving detemir/glargine either once or twice daily
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Discussion
In parallel–series randomized clinical trials comparing 
degludec with either glargine or detemir, degludec doses 
at endpoint are usually lower than those of comparators, 
both in type 1 [8–10, 14, 15] and type 2 [6, 16, 17] dia-
betes. The reduction of basal insulin doses with degludec 
in clinical trials appears to be greater in patients previ-
ously receiving two daily injections of basal insulin [4, 8]. 
In several trials, degludec use was also associated with a 
lower dose of prandial insulin than comparators [6, 7, 9, 
10, 14, 15], although some studies failed to detect this dif-
ference [8]. In a 2-week crossover trial on a small sample 
of patients with type 1 diabetes, degludec was associated 
with a lower dose of prandial, but not basal, insulin when 
compared to glargine [18].
Randomized clinical trials are the ideal tool for explor-
ing the efficacy and safety of any new treatment, but they 
do not necessarily provide an accurate picture of real-life 
conditions. With respect to the aim of this study, i.e., 
changes in insulin doses when switching from glargine 
or detemir to degludec, randomized trials could produce 
some biases. In fact, titration schedules for basal insulin in 
those studies follow algorithms based on morning fasting 
glucose, which may be rather different from those used for 
adjustment of insulin doses in routine clinical practice [19, 
20]. Notably, the kinetics of degludec is considerably dif-
ferent from those of both glargine and detemir, producing, 
if they are all administered at bedtime, higher circulating 
insulin concentrations in the afternoon [21, 22]. As a con-
sequence, it is conceivable that clinicians titrate deglu-
dec considering pre-dinner glucose along with morning 
fasting glycemia. In addition, patients enrolled in clinical 
trials are not necessarily representative of those receiving 
basal insulin in clinical practice. For all those reasons, 
observational studies can add some information on dose 
adjustments when switching from glargine or detemir to 
degludec.
There are a small number of prospective observational 
studies assessing the change in basal and prandial insu-
lin needs in patients switching from other basal insulin 
analogues to degludec. In patients with type 1 diabetes, a 
significant reduction has been reported for prandial insulin 
doses, whereas a reduction of basal insulin doses occurred 
only in patients previously treated with two daily injec-
tions of basal insulin [23, 24]; conversely, no significant 
variation of either prandial or basal insulin doses was 
observed in type 2 diabetes [23].
Prospective observational studies have the advantage 
of collecting pre-defined data in a controlled setting. On 
the other hand, prospective observations tend to alter the 
spontaneous behaviors of both clinicians and patients. 
Therefore, retrospective observational studies, despite 
the limitation related to the possible incompleteness of 
data, may be closer to actual clinical practice. To our 
knowledge, only one such retrospective study exploring 
the change of insulin doses after switch to degludec is 
available so far. It is a survey on 360 patients with type 
1 diabetes, reporting a reduction of basal insulin dose 
in those switching from detemir to degludec, but not in 
patients switching from glargine to degludec [25]. Due to 
its shorter duration of action, detemir is used twice daily in 
type 1 diabetes more often than glargine [26, 27]; unfortu-
nately, in the retrospective study reported above, no sepa-
rate analysis was performed on patients previously treated 
with basal insulin either once or twice daily. This point is 
relevant, considering that, both in randomized trials and 
prospective observational studies, the reduction of basal 
insulin doses is more evident in patients previously treated 
with twice-daily basal insulin [28].
The present study shows a significant reduction of basal 
insulin when switching from twice-daily glargine or detemir 
to once daily degludec in type 1 diabetes, whereas only a 
nonsignificant trend was observed in those switching from 
once daily basal insulin. These results confirm those reported 
in clinical trials and prospective observations [8–10, 13–15, 
23, 24, 28]. In addition, a reduction of prandial insulin doses 
was observed after the switch, irrespective of the number of 
previous daily basal insulin injections [13, 18, 23]. Nota-
bly, the reduction of insulin doses occurred together with 
an improvement of glycemic control, as reported by some 
previous studies [13, 23, 28].
The data collected in this retrospective observation 
were used for developing simple equations, to calculate the 
needed adjustment of insulin doses when switching from 
glargine or detemir to degludec in type 1 diabetes. As a rule 
of the thumb, in patients previously treated with once daily 
basal insulin, basal insulin doses should be reduced by 20%, 
adding 3 UI; in patients previously on twice-daily basal insu-
lin, degludec dose should be about 30% lower than that of 
prior basal insulin. In addition, a 20% reduction of prandial 
insulin doses should be recommended, irrespective of the 
number of daily basal insulin injections before the switch.
The variations of both basal and prandial insulin doses in 
type 2 diabetes appear to be consistent with those observed 
in patients with type 1 diabetes. In the present sample, the 
large majority of patients with type 2 diabetes switching to 
degludec was on basal-bolus therapy; therefore, this study 
cannot provide reliable information on dose adjustments in 
patients on basal insulin only.
The small size of the sample enrolled in the present 
study warrants caution in the interpretation of results. 
In addition, this retrospective survey was performed in 
a single specialist clinic for diabetes care, limiting the 
generalizability of results. In fact, type 1 diabetic patients 
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switching from other basal insulins to degludec are not 
representative of all those with type 1 diabetes. Further-
more, the specific clinical context, in which patients were 
regularly visited by trained specialists, could have affected 
dose titration. The proposed algorithm for dose titration in 
the switch should, therefore, be validated through specifi-
cally designed studies. It should also be recognized that 
the available sample of patients with type 2 diabetes is 
very small, so that those specific results should be intended 
as preliminary. Another limitation is represented by the 
lack of data on mean fasting glucose, which is impossible 
to standardize in retrospective studies. The retrospective 
nature of the study does not allow the retrieval of reliable 
information on total and nocturnal hypoglycemia, whereas 
the incidence of severe hypoglycemia is too low to pro-
duce meaningful results on this sample size. Furthermore, 
the retrospective nature of the study does not allow the 
retrieval of information which is not part of routine clini-
cal practice, such as an accurate study of insulin secretory 
status, or structured data on daily glucose profiles derived 
from either capillary glucose self-monitoring or continu-
ous glucose monitoring.
Despite these limitations, the present results provide 
a suggestion for a simple method for the adjustment of 
basal and prandial insulin doses in patients with type 1 
diabetes switching from glargine or detemir to degludec, 
which deserves further investigation.
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